Acute cellular and antibody-mediated rejection of the pancreas allograft: Incidence, risk factors and outcomes

American Journal of Transplantation

Volumn 13, Issue 11, 2013, Pages 2945-2955

  Niederhaus, S V ^a,b   Leverson, G E ^a   Lorentzen, D F ^a   Robillard, D J ^a   Sollinger, H W ^a   Pirsch, J D ^a   Torrealba, J R ^a,c   Odorico, J S ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^b UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

^c UNIVERSITY OF TEXAS AT DALLAS   (United States)

Author keywords

Antibody mediated rejection; biopsy; cellular rejection; donor specific antibody; kidney transplantation; outcomes; pancreas transplantation

Indexed keywords

COMPLEMENT COMPONENT C4D;

ACUTE GRAFT REJECTION; ADULT; AGED; ALLOGRAFT; ANTIBODY MEDIATED REJECTION; ARTICLE; FEMALE; GRAFT SURVIVAL; HUMAN; HUMAN CELL; INCIDENCE; KIDNEY PANCREAS TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS TRANSPLANTATION; PRIORITY JOURNAL; RISK FACTOR; SURVIVAL RATE;

ANTIBODY-MEDIATED REJECTION; BIOPSY; CELLULAR REJECTION; DONOR-SPECIFIC ANTIBODY; KIDNEY TRANSPLANTATION; OUTCOMES; PANCREAS TRANSPLANTATION;

ADULT; ALLOGRAFTS; COMPLEMENT C4B; FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNITY, CELLULAR; INCIDENCE; ISOANTIBODIES; MALE; PANCREAS TRANSPLANTATION; PEPTIDE FRAGMENTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; ROC CURVE; SURVIVAL RATE; WISCONSIN;

EID: 84886797580     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.12443     Document Type: Article

References (21)

1. Melcher ML, Olson JL, Baxter-Lowe LA, Stock PG, Posselt AM., Antibody-mediated rejection of a pancreas allograft. Am J Transplant 2006; 6: 423-428.
2. Pascual J, Samaniego MD, Torrealba JR, et al. Antibody-mediated rejection of the kidney after simultaneous pancreas-kidney transplantation. J Am Soc Nephrol 2008; 19: 812-824.
3. Torrealba JR, Samaniego M, Pascual J, et al. C4d-positive interacinar capillaries correlates with donor-specific antibody-mediated rejection in pancreas allografts. Transplantation 2008; 86: 1849-1856.
4. Torrealba JR, Odorico JS., Antibody-mediated rejection of the pancreas allograft. Transplantation 2009; 88: 292-293.
5. Rangel EB, Malheiros DM, de Castro MC, et al. Antibody-mediated rejection (AMR) after pancreas and pancreas-kidney transplantation. Transplant Int 2010; 23: 602-610.
6. Prikis M, Normal D, Rayhill S, Olysei A, Troxell M, Mittalhenkle A., Preserved endocrine function in a pancreas transplant recipient with pancreatic panniculitis and antibody-mediated rejection. Am J Transplant 2010; 10: 2717-2722.
7. Sis B, Mengel M, Haas M, et al. Banff '09 Meeting Report: Antibody mediated graft deterioration and implementation of Banff Working Groups. Am J Transplant 2010; 10: 464-471.
8. Behr TM, Feucht HE, Richter K, et al. Detection of humoral rejection in human cardiac allografts by assessing the capillary deposition of complement fragment C4d in endomyocardial biopsies. J Heart Lung Transplant 1999; 18: 904-912.
9. Drachenberg CB, Odorico J, Demetris AJ, et al. Banff schema for grading pancreas allograft rejection: Working proposal by a multi-disciplinary international consensus panel. Am J Transplant 2008; 8: 1237-1249.
10. Drachenberg CB, Torrealba JR, Nankivell BJ, et al. Guidelines for the diagnosis of antibody-mediated rejection in pancreas allografts-updated Banff grading schema. Am J Transplant 2011; 11: 1792-1802.
11. Drachenberg CB, Papadimitriou JC., Graft dysfunction in pancreas and islet transplantation: Morphological aspects. Curr Opin Organ Transplant 2011; 16: 106-109.
12. Pascual J, Pirsch JD, Odorico JS, et al. Alemtuzumab induction and antibody-mediated kidney rejection after simultaneous pancreas-kidney transplantation. Transplantation 2009; 87: 125-132.
13. Heilman RL, Chakkera H, Mazur M, et al. Outcomes of simultaneous kidney-pancreas transplantation with positive cross-match. Transplant Proc 2009; 41: 303-306.
14. Niederhaus SV, Muth B, Lorentzen DF, et al. Luminex-based desensitization protocols: The University of Wisconsin initial experience. Transplantation 2011; 92: 12-17.
15. Jordan SC, Pescovitz MD., Presensitization: The problem and its management. Clin J Am Soc Nephrol 2006; 1: 421-432.
16. Stegall MD, Diwan T, Raghavaiah S, et al. Terminal complement inhibition decreases antibody-mediated rejection in sensitized renal transplant recipients. Am J Transplant 2011; 11: 2405-2413.
17. Willicombe M, Roufosse C, Brookes P, et al. Antibody-mediated rejection after alemtuzumab induction: incidence, risk factors, and predictors of poor outcome. Transplantation 2011; 92: 176-182.
18. Cantarovich D, De Amicis S, Akl A, et al. Posttransplant donor-specific anti-HLA antibodies negatively impact pancreas transplantation outcome. Am J Transplant 2011; 11: 2737-2746.
19. Archdeacon P, Chan M, Neuland C, et al. Summary of FDA antibody-mediated rejection workshop. Am J Transplant 2011; 11: 896-906.
20. De Kort H, Munivenkatappa RB, Berger SP, et al. Pancreas allograft biopsies with positive C4d staining and anti-donor antibodies related to worse outcome for patients. Am J Transplant 2010; 10: 1669-1676.
21. Wiebe C, Nickerson P., Posttransplant monitoring of de novo human leukocyte antigen donor-specific antibodies in kidney transplantation. Curr Opin Organ Transplant 2013; 18: 470-477.